Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Tikagrelor untuk sindrom koroner akut

Penilaian teknologi kesehatan PTK-B01AC24 Draf untuk telaah Diperbarui 14 Juni 2026

1. Usulan rekomendasi

Diusulkan untuk direkomendasikan

Tikagrelor diusulkan untuk direkomendasikan untuk sindrom koroner akut.

Alasan usulan

  • Dibandingkan dengan klopidogrel ditambah aspirin, tikagrelor memberi tambahan 0,20 tahun hidup berkualitas (QALY) per pasien dengan tambahan biaya Rp 8,3 juta per pasien.
  • Rasio biaya terhadap manfaat sebesar Rp 42,3 juta per QALY berada di bawah acuan satu kali PDB per kapita (Rp 75 juta per QALY).

2. Informasi tentang tikagrelor

Nama generikTikagrelor (ticagrelor)
Kode ATCB01AC24
Bidang terapiDarah dan organ pembentuk darah
Program penilaianPenilaian obat baru
Intervensi yang dinilaiTikagrelor ditambah aspirin
Pembandingklopidogrel ditambah aspirin
Formularium NasionalTercantum (FKRTL)
Izin edar BPOMYa
Katalog elektronik pengadaanYa
Daftar Obat Esensial WHOYa
Perluasan akses FKTPReasesmen 3: Hanya dijamin di FKRTL dan tercantum dalam Daftar Obat Esensial WHO, atau sudah memiliki penilaian teknologi kesehatan.
Biaya obat dalam model (per tahun atau per rangkaian terapi)Rp 6 juta

3. Pembahasan bukti

UkuranNilai
Tambahan tahun hidup berkualitas per pasien0,197 QALY
Tambahan biaya per pasienRp 8,3 juta
Rasio biaya terhadap manfaatRp 42,3 juta per QALY
Peluang hemat biaya pada Rp 75 juta per QALY84,4%

Hasil lengkap, termasuk simulasi probabilistik dan analisis sensitivitas, tersedia pada halaman bukti.

Keterbatasan

Uraian berikut tersedia dalam bahasa Inggris.

  • Drug-acquisition costs are the authoritative Indonesian e-Katalog LKPP (BPJS procurement) net prices (ticagrelor 90 mg Rp 8,325/tab; clopidogrel 75 mg Rp 715/tab); these resolve the single most influential divergence between the two independent builders, who had both used unverified retail/generic proxies. e-Katalog tender prices can change between procurement cycles and should be re-confirmed.
  • Treatment effect is confined to the 12-month DAPT window per the NICE TA236 economic model (paragraph 3.11: the beneficial effect of ticagrelor does not persist beyond 1 year); both independent builder arms had instead let the PLATO hazard ratios persist across the full modelled horizon, which materially overstated incremental QALYs. The adjudicated model corrects this by applying the HRs to year-1 transitions only and using identical year>=2 transition probabilities for both arms.
  • PLATO efficacy hazard ratios are from a global RCT; East Asian / Indonesian patients may differ in ischaemic and bleeding risk, and some East Asian data suggest higher bleeding with potent P2Y12 inhibitors. The stroke HR (1.17) and major-bleeding HR (1.04) were not statistically significant in PLATO but are retained at their point estimates for fidelity and tested in PSA.
  • PLATO data integrity was questioned in a 2024 BMJ investigation; the published HRs are used here as the regulatory/NICE-accepted base case, with this caveat flagged for expert review.
  • Indonesia-specific post-ACS transition probabilities, EQ-5D health-state utilities, and INA-CBG cardiovascular tariff codes were not directly available; values are calibrated to PLATO, NICE TA236, UK fallback utilities, and Indonesian ACS registry mortality, requiring local validation (SKI, JKN claims, SMART-REACH inpatient cost data).
  • The model represents ticagrelor bleeding/dyspnoea harms as a per-cycle disutility, a small added care cost, and an explicit post_major_bleed state, rather than as fully time-resolved transient bleeding events; twice-daily adherence below trial levels would attenuate real-world benefit and is not modelled in the base case.
  • Chronic (year >=2) post-ACS background event and mortality rates are extrapolations from secondary-prevention literature and the NICE TA236 Markov assumptions, not an Indonesia-specific longitudinal ACS cohort.

4. Implementasi

Dengan perkiraan 250.000 pasien yang memenuhi syarat, dampak anggaran kumulatif lima tahun diperkirakan tambahan belanja Rp 1,8 triliun. Rincian per tahun tersedia pada halaman implementasi.

Penilaian kapasitas layanan, kesiapan implementasi, dan kesetaraan belum tersedia untuk topik ini.

5. Tim penilai dan status telaah

Status telaahDraf, menunggu telaah ahli ekonomi kesehatan
Penyusun analisisARC Institute
Pengesahan komiteBelum ada